This review will cover recent advances in the field of medicinal chemistry towards small-molecule BTK inhibitors under clinical trials for the treatment of inflammatory and autoimmune diseases, including RA, SS, MS, SLE, urticaria, pemphigus, ITP, and RD. The gene discussed is BTK; the disease is autoimmune thrombocytopenic purpura.